Trial of Celecoxib in Amyotrophic Lateral Sclerosis
Study Purpose:
To determine whether chronic treatment with celecoxib, a cyclooxygenase-2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS).
Disease:
Amyotrophic Lateral Sclerosis (ALS), Familial ALS, Sporadic ALSStudy Type:
Interventional TrialStudy Category:
Drug TrialStudy Status:
Not enrollingPhase:
Study Chair(s)/Principal Investigator(s):
Merit Cudkowicz, Massachusetts General Hospital
Clinicaltrials.gov ID (11 digit #):
Neals Affiliated?
YesCoordinating Center Contact Information
.(JavaScript must be enabled to view this email address)
.(JavaScript must be enabled to view this email address)
Full Study Summary:
Study Sponsor:
Participant Duration:
12 months